{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:54Z","timestamp":1758050334433,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bulcan.2022.04.017","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:21:02Z","timestamp":1656746462000},"page":"S108-S115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Place de l\u2019allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques apr\u00e8s traitement par CAR T-cell anti-CD19\u00a0: recommandations de la SFGM-TC"],"prefix":"10.1016","volume":"110","author":[{"given":"David","family":"Beauvais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Diral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Vandewiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Yakouben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.04.017_bib0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0220","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0225","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19\u00a0CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19\u00a0for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2\u00a0results of the single-arm, open-label, multicentre ZUMA-3\u00a0study","author":"Shah","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0235","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0240","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41409-019-0702-2","article-title":"Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party","volume":"55","author":"Bazarbachi","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0250","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2\u00a0trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2\u00a0trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2\u00a0study","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0265","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0270","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0275","first-page":"1674","article-title":"Integrating CAR T-Cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-Cell or chemotherapy-based complete remission in B-Cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19\u00a0CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0285","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-Cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0290","doi-asserted-by":"crossref","first-page":"651944","DOI":"10.3389\/fonc.2021.651944","article-title":"Consolidative hematopoietic stem cell transplantation after CD19\u00a0CAR-T cell therapy for acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0295","article-title":"Factors associated with treatment response to CD19\u00a0CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0300","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy","author":"Barz Leahy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0305","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","author":"Myers","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0310","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0315","article-title":"Next-Generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","author":"Pulsipher","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0320","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8\u00a0T-Cell selection affects chimeric antigen receptor (CAR) T-Cell potency and toxicity: updated results from a phase I Anti-CD22\u00a0CAR T-Cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0325","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19\u00a0and CD22\u00a0for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0330","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the acute leukaemia working party of the european society for blood and marrow transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0335","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0340","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0345","article-title":"T-Cell therapy response using genome-wide sequencing of cell-free DNA in patients with B-Cell lymphomas","author":"Goodman","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0350","doi-asserted-by":"crossref","first-page":"611710","DOI":"10.3389\/fimmu.2020.611710","article-title":"How to combine the two landmark treatment methods-allogeneic hematopoietic stem cell transplantation and chimeric antigen receptor T Cell therapy together to cure high-risk B Cell acute lymphoblastic leukemia?","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0355","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17460","article-title":"The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy","author":"Dholaria","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0360","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T Cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0365","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19\u00a0CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0370","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19\u00a0chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1\u00a0dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0375","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19\u00a0CAR T-cell therapy in 110\u00a0patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0380","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19\u00a0chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0385","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19\u00a0CAR-T cells of defined CD4+:CD8+ composition in adult B cell all patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0390","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19\u00a0chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0395","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0400","article-title":"KTE-X19\u00a0anti-CD19\u00a0CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3\u00a0phase 1\u00a0results","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0405","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0410","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0415","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-cd19\u00a0chimeric antigen receptor t cells are associated with high serum interleukin-15\u00a0Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.017_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:33Z","timestamp":1757792253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0007455122001941"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Place de l\u2019allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques apr\u00e8s traitement par CAR T-cell anti-CD19\u00a0: recommandations de la SFGM-TC","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}